. These common variants have replicable but small effects on LOAD risk and generally do not have obvious functional effects. Low-frequency coding variants, not detected by GWAS, are predicted to include functional variants with larger effects on risk. To identify low-frequency coding variants with large effects on LOAD risk, we carried out wholeexome sequencing (WES) in 14 large LOAD families and follow-up analyses of the candidate variants in several large LOAD case-control data sets. A rare variant in PLD3 (phospholipase D3; Val232Met) segregated with disease status in two independent families and doubled risk for Alzheimer's disease in seven independent case-control series with a total of more than 11,000 cases and controls of European descent. Gene-based burden analyses in 4,387 cases and controls of European descent and 302 African American cases and controls, with complete sequence data for PLD3, reveal that several variants in this gene increase risk for Alzheimer's disease in both populations. PLD3 is highly expressed in brain regions that are vulnerable to Alzheimer's disease pathology, including hippocampus and cortex, and is expressed at significantly lower levels in neurons from Alzheimer's disease brains compared to control brains. Overexpression of PLD3 leads to a significant decrease in intracellular amyloid-b precursor protein (APP) and extracellular Ab42 and Ab40 (the 42-and 40-residue isoforms of the amyloid-b peptide), and knockdown of PLD3 leads to a significant increase in extracellular Ab42 and Ab40. Together, our genetic and functional data indicate that carriers of PLD3 coding variants have a twofold increased risk for LOAD and that PLD3 influences APP processing. This study provides an example of how densely affected families may help to identify rare variants with large effects on risk for disease or other complex traits.
The identification of pathogenic mutations in APP, presenilin 1 (PSEN1) and PSEN2, and the association of apolipoprotein E (APOE) genotype with disease risk led to a better understanding of the pathobiology of Alzheimer's disease, and the development of novel animal models and therapies for this disease 3 . Recent studies using next-generation sequencing have also identified a protective variant in APP 4 , and a lowfrequency variant in TREM2 associated with Alzheimer's disease risk [5] [6] [7] [8] with odds ratio close to that of one APOE4 allele. These studies have led to the identification of functional variants with large effects on Alzheimer's disease pathogenesis, in contrast to the loci identified through GWAS 1, 2 . Low-frequency coding variants not detected by GWAS may be a source of functional variants with a large effect on LOAD risk [5] [6] [7] [8] ; however, the identification of such variants remains challenging because most study designs require WES in very large data sets. One potential solution is to perform WES or whole-genome-sequencing in a highly selected population at increased risk for disease followed by a combination of genotyping and deep re-sequencing of the variant or gene of interest in large numbers of cases and controls.
We reported previously that families with a clinical history of LOAD in four or more individuals are enriched for genetic risk variants in known Alzheimer's disease and frontotemporal dementia (FTD) genes, but some of these families do not carry pathogenic mutations in the known Alzheimer's disease or FTD genes 9, 10 , suggesting that additional genes may contribute to LOAD risk. We ranked 868 LOAD families from the National Institute on Aging (NIA)-LOAD study based on number of affected individuals, number of generations affected, the number of affected and unaffected individuals with DNA available, the number of individuals with a definite or probable diagnosis of Alzheimer's disease, early age at onset (AAO) and APOE genotype (discarding families in which APOE4 segregates with disease status), and 14 were selected to perform WES. In the 14 selected families, there were at least four affected individuals per family, with DNA available for at least three of these individuals. We sequenced at least two affected individuals per family, prioritizing distantly related affected individuals with the earliest AAO. We also sequenced one unaffected individual in nine families and two unaffected individuals in one family. In total, we performed WES on 29 affected individuals and 11 unaffected individuals from 14 families of European American ancestry (Supplementary Table 1 and Supplementary Fig. 2 ).
All variants shared by affected individuals but absent in unaffected individuals within a family, with a minor allele frequency (MAF) lower than 0.5% in the Exome Variant Server (EVS; http://evs.gs.washington. edu/EVS/) were selected and genotyped in the remaining family members to determine segregation with disease (Supplementary Information). We next examined whether individual variants or variants in the same gene segregated with disease in more than one family. A single variant, rs145999145 (Val232Met, PLD3, chromosome 19q13.2), segregated with disease in two independent families ( Fig. 1 and Supplementary  Fig. 1 ). We then sought to determine whether this variant was associated with increased risk for sporadic Alzheimer's disease in seven independent data sets (4,998 Alzheimer's disease cases and 6,356 controls of European descent from the Knight Alzheimer's Disease Research Centre (ADRC), NIA-LOAD, NIA-UK data set, Cache-County study, the Universities of Toronto, Nottingham and Pittsburgh, the National Institutes of Mental Health (NIMH) Alzheimer's disease series, and the Wellderly study 7, [11] [12] [13] [14] ; Extended Data Table 1 ). PLD3(V232M) was associated with both Alzheimer's disease risk (P 5 2.93 3 10
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, odds ratio 5 2.10, 95% CI 5 1.47-2.99; Table 1 ) and AAO (P 5 3 3 10
23
; Extended Data Fig. 1 ). The frequency of PLD3(V232M) was higher in Alzheimer's disease cases compared to controls in each age-genderethnicity matched data set, with a similar estimated odds ratio for each data set (Extended Data Table 1 and Extended Data Fig. 2) , suggesting that the association is unlikely to be a false positive due to population stratification. This was confirmed when population principal components derived from GWAS data were included (Supplementary Information, and Supplementary Figs 2 and 3) . The association of the Val232Met variant with Alzheimer's disease risk was also independent of APOE genotype (Supplementary Information, Supplementary Table 3 and Supplementary Fig. 4) .
LOAD risk variants, such as APOE4, are most common in Alzheimer's disease cases with a family history of disease and least common in elderly controls without disease 8, 9 . We examined the frequency of Val232Met in three groups of elderly individuals without dementia stratified by age (.65 years, .70 years and .80 years; Table 4 ). As proposed, the frequency of Val232Met was higher in familial cases than in sporadic cases (2.62% in familial versus 1.36% in sporadic cases). Several risk variants have been observed in APP, PSEN1 and PSEN2 and APOE, supporting the role of these genes in Alzheimer's disease risk 3, 4 . To identify additional risk variants in PLD3, we sequenced the PLD3 coding region in 2,363 cases and 2,024 controls of European descent (Extended Data Tables 2 and 3 ). Fourteen variants were observed more frequently in cases than in controls, including nine variants that were unique to cases (Fig. 2a and Supplementary Information) . The genebased burden analysis resulted in a genome-wide significant association of carriers of PLD3 coding variants among Alzheimer's disease cases (7.99%) compared to controls (3.06%; P 5 1.443 10
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; odds ratio 5 2.75, 95% CI 5 2.05-3.68). When the Val232Met variant was excluded, the association remained highly significant, still passing genome-wide multipletest correction (P 5 1.58 3 10
28
; odds ratio 5 2.58, 95% CI 5 1.87-3.57; Extended Data Table 3 ), indicating that there are additional variants in PLD3 that increase risk for Alzheimer's disease independent of Val232Met. There were two additional highly conserved variants ( Supplementary  Fig. 5 ), that were nominally associated with LOAD risk: Met6Arg (P 5 0.02; odds ratio 5 7.73, 95% CI 5 1.09-61), and Ala442Ala (P 5 3.783 10
27
; odds ratio 5 2.12, 95% CI 5 1.58-2.83). The Ala442Ala variant showed an association with LOAD risk in four independent series (Extended Data Table 4 ). This variant was included in the gene-based analysis because our bioinformatic and functional analyses indicate that this variant affects splicing and gene expression (see below).
If the association of PLD3 with Alzheimer's disease risk is real, it is possible that rare coding variants in PLD3 in other populations will also increase risk for Alzheimer's disease. We therefore sequenced PLD3 in 302 African American Alzheimer's disease cases and controls. Both the Val232Met and the Ala442Ala variants were found in Alzheimer's disease cases but not controls, and the Ala442Ala variant showed a significant association with Alzheimer's disease risk (P 5 0.03). There was also a significant association with LOAD risk at the gene level (P 5 1.4 3 10
23
; odds ratio 5 5.48, 95% CI 5 1.77-16.92; Fig. 1 , Extended Data Table 5 and Supplementary Information). This consistent evidence of association with Alzheimer's disease risk, at the single-nucleotide polymorphism (SNP) and gene level in two different populations strongly supports PLD3 as an Alzheimer's disease risk gene.
To begin to understand the link between PLD3 and Alzheimer's disease, we analysed PLD3 expression in Alzheimer's disease case and control brains. In human brain tissue from cognitively normal individuals, PLD3 showed high levels of expression in the frontal, temporal and occipital cortices and hippocampus ( Supplementary Fig. 6 ). Using data from gene expression in laser-captured neurons from Alzheimer's disease cases and controls, PLD3 gene expression was significantly lower in Alzheimer's disease cases compared to controls (P 5 8.103 10
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; Fig. 2b ). This result was replicated in three additional independent data sets (Supplementary Information and Extended Data Fig. 3 ). Bioinformatic analyses predicted that the Ala442Ala variant affects alternative splicing (Supplementary Fig. 7 and Supplementary Information). We found that Ala442Ala is associated with lower levels of total PLD3 messenger RNA ( Fig. 2D ) and lower levels of transcripts containing exon 11 ( Fig. 2c and Supplementary Fig. 8 ), supporting the functional effect of this variant.
PLD3 is a non-classical, poorly characterized member of the PLD superfamily of phospholipases. PLD1 and PLD2 have been previously implicated in APP trafficking and Alzheimer's disease [15] [16] [17] . To determine whether PLD3 also affects APP processing, wild-type human PLD3 was overexpressed in mouse neuroblastoma (N2A) cells that stably express wild-type human APP695 (APP695-WT; cells termed N2A-695). In this system extracellular Ab42 and Ab40 were decreased by 48% and 58%, respectively, compared to the empty vector (P , 0.0001; Fig. 3a ). Conversely, knockdown of endogenous PLD3 expression by short hairpin RNA (shRNA) in N2A-695 cells resulted in higher levels of extracellular Ab42 and Ab40 than in cells transfected with scrambled shRNA (Fig. 3b) . To determine whether the observed effects on APP processing were unique to PLD3 or common among the phospholipase D protein family, we co-expressed APP695-WT with PLD1, PLD2 and PLD3 in human embryonic kidney (HEK293T) cells. Overexpression of PLD3, but not empty vector, PLD1 or PLD2, resulted in a substantial decrease in full-length APP levels (Fig. 3c) . Extracellular Ab42 and Ab40 levels were significantly reduced in cells overexpressing PLD1, PLD2 and PLD3 compared to control (Fig. 3c) . Interestingly, overexpression of catalytically inactive PLD1 and PLD2 variants (PLD1(K898R) and PLD2(K758R)) restored extracellular Ab42 and Ab40 levels to control values, demonstrating that this is in part a phospholipaseactivity-dependent effect (Fig. 3c ). Overexpression of a PLD3 dominantnegative variant (PLD3(K418R)) that inhibits myotube formation 18 failed to restore full-length APP and Ab42 and Ab40 to normal levels (Fig. 3c) . Furthermore, PLD3 can be co-immunoprecipitated with APP in cultured cells (Extended Data Fig. 4) . Together, these studies demonstrate that PLD3 has a role in APP processing that is functionally distinct from PLD1 and PLD2. These findings are consistent with the human The scheme also shows the exon composition of the longest PLD3 mRNA and the position of the variants found in this study. *Variants significantly associated with Alzheimer's disease risk. {Variants found only in Alzheimer's disease cases. {Variants that are more frequent in Alzheimer's disease cases than in controls. b, PLD3 neuronal gene expression is significantly lower in Alzheimer's disease cases compared to controls. We used the Gene Expression Omnibus data set GSE5281 (ref. 26) , in which neurons were laser-captured to analyse whether PLD3 mRNA expression levels are different between Alzheimer's disease cases and cognitively normal elderly individuals. c, d, The PLD3(A442A) variant is associated with lower total PLD3 mRNA expression and lower levels of exon11 containing transcripts. Primers specific to exons 7, to 11 (two pairs of primers) were designed with PrimerExpress (c). cDNA from 8 PLD3(A442A) carriers and 10 age-, gender-, APOE-, clinical dementia rating (CDR)-and post-mortem interval (PMI)-matched individuals were extracted from parietal lobe. Relative expression of exon 11 compared to the other exons was calculated by the DCt (changes in cycle threshold) method. Exon-11-containing transcripts were 20% lower in Ala442Ala carriers (P , 0.05) in comparison to exon-7-10-containing transcripts. Graphs represent the mean 6 s.e.m. Real-time PCR was used to quantify total PLD3 mRNA and standardized using GADPH mRNA as a reference (d). P value in d is for the gene-expression levels of major allele carriers versus minor allele carriers after correcting for dementia severity.
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genetic and brain expression data presented above; lower PLD3 expression and function is correlated with higher APP and amyloid-b levels and with more extensive Alzheimer's-disease-specific pathology (Supplementary Table 4 ).
Here we provide extensive genetic evidence that PLD3 is an Alzheimer's disease risk gene: genome-wide significant evidence that rare variants in PLD3 increase risk for Alzheimer's disease in multiple data sets and two populations. In addition, our functional studies confirm that PLD3 affects APP processing, in a manner that is consistent with increased risk for Alzheimer's disease 3, 19 . This work also provides a second example of a novel gene containing rare variants that influence risk for Alzheimer's disease 5, 7, 8 . Although these variants have low population attributable fraction (proportion of cases in the population attributable to PLD3 variants) and diagnostic utility owing to their rarity, they provide important and novel insights into Alzheimer's disease pathogenesis. Our success in identifying multiple families carrying the Val232Met variant and the enrichment of this variant in LOAD families compared to sporadic Alzheimer's disease cases demonstrates the power of using a highly selected sample of multiplex LOAD families for variant discovery. The studies on TREM2 (refs [5] [6] [7] [8] , and this report, suggest that nextgeneration sequencing projects will identify additional low-frequency and rare variants associated with Alzheimer's disease.
METHODS SUMMARY
Participants. Samples were obtained from seven independent data sets totalling 4,998 Alzheimer's disease cases and 6,356 controls of European descent from the Knight ADRC, NIA-LOAD, NIA-UK data set, Cache-County study, the Universities of Toronto, Nottingham and Pittsburgh, the NIMH-AD series, and the Wellderly study 7, [11] [12] [13] [14] . Exome sequencing. Enrichment of coding exons and flanking intronic regions was carried out using a solution hybrid selection method with the SureSelect human all exon 50-Mb kit (Agilent Technologies) as previously described 20 . SNP genotyping. SNPs were genotyped using the Illumina Golden Gate, Sequenom, KASPar 21, 22 and/or Taqman. PLD3 sequencing. PLD3 was sequenced using a pooled-DNA sequencing design as described previously 9, 23, 24 . All rare missense or splice site variants were then validated by Sequenom and KASPar genotyping. Gene-expression and alternative splicing analyses. Total RNA was extracted using the RNeasy mini kit (Qiagen). Complementary DNA was prepared from the total RNA, using the High-Capacity cDNA Archive kit (ABI). Gene-expression levels were analysed by real-time polymerase chain reaction (PCR), using an ABI-7900 real-time PCR system. Statistical analyses. All of the single SNP analyses were performed using a Fisher's exact test. Allelic association with risk for Alzheimer's disease was tested using 'proc logistic' in SAS, including APOE genotype, age, principal component (PC) factors, from population stratification analyses and study as covariates when available. Genebased analyses were performed using the optimal SNP-set Kernel Association Test (SKAT-O) 25 . Cell-based studies. To assess the effects of PLD3 expression on APP cleavage, vectors containing PLD3-WT or PLD3 shRNA were transiently transfected in mouse N2A cells stably expressing human APP695-WT. Ab40 and Ab42 were measured in conditioned media by enzyme-linked immunosorbant assay (ELISA) (Invitrogen). PLD3 silencing was confirmed by quantitative PCR (qPCR). To assess the effects of PLD proteins on APP cleavage, HEK293T cells were transiently transfected with vectors containing PLD1, PLD2 and PLD3-WT or dominant-negative mutations. Ab40 and Ab42 were measured in conditioned media by ELISA. Full-length APP levels were measured by immunoblot analysis of cell lysates.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. Author Information The authors declare competing financial interests: details are available in the online version of the paper. Exome-sequencing data is available on NIAGADs (https://www.niagads.org, accession number NG00033). Reprints and permissions information is available at www.nature.com/reprints. Readers are welcome to comment on the online version of the paper. Correspondence and requests for materials should be addressed to C.C. (ccruchaga@wustl.edu). 27 . Cerebrospinal fluid (CSF) levels data set: A subset (n 5 528) of the Knight-ADRC samples had total tau protein and Ab42 levels measured in the CSF by ELISA. Of these, 528, 303 did not have dementia (CDR 5 0) and were elderly (over 65 years of age), with high CSF Ab42 levels (.500 pg ml
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). A description of the CSF data set used in this study can be found in another paper 11 . CSF collection and Ab42, tau and phosphorylated tau181 measurements were performed as described previously 28 .
NIA-LOAD. Participants from the National Institute of Ageing Late Onset
Alzheimer Disease (NIA-LOAD) Family Study included a single individual with dementia from each of 868 families with at least three Alzheimer's disease-affected individuals, and 881 unrelated control individuals who were elderly and did not have dementia (545 individuals were older than 70 years of age). All Alzheimer's disease cases were diagnosed with dementia of the Alzheimer's type (DAT) using criteria equivalent to the National Institute of Neurological and Communication Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) for probable Alzheimer's disease 29 . NIA-LOAD families were ascertained based on the following criteria: probands (the affected individual through whom the family was recruited into the study) were required to have a diagnosis of definite or probable LOAD (onset after 60 years of age) and a sibling with definite, probable or possible LOAD with a similar age at onset. A third biologically related family member (first, second or third degree) was also required, regardless of affection status. This individual had to be $60 years of age if unaffected, or $50 years of age if diagnosed with LOAD or mild cognitive impairment 12 . Within each pedigree, we selected a single individual for the case-control series by identifying the youngest affected family member with the most definitive diagnosis (that is, individuals with autopsy confirmation were chosen over those with clinical diagnosis only). Unrelated controls without dementia who were used for the NIA-LOAD case-control series had no family history of Alzheimer's disease and were matched to the cases as previously described 12 . Only individuals of European descent based on the principal component (PC) factors from population stratification analyses were included. Written informed consent was obtained from all participants, and the study was approved by local IRB committees. Wellderly Study. The Scripps Translational Science Institute's Wellderly study has recruited more than 1,000 healthy elderly participants. Inclusion criteria specify informed consent, age .80 years, blood or saliva donation, compliance with protocol-specified procedures, and no or mild ageing-related medical conditions. Exclusion criteria includes self-reported cancer (excluding basal and squamous cell skin cancer), coronary artery disease or myocardial infarction, stroke or transient ischaemic attack, deep vein thrombosis or pulmonary embolism, chronic renal failure or haemodialysis, Alzheimer's or Parkinson's disease, diabetes, aortic or cerebral aneurysm, or the use of oral chemotherapeutic agents, anti-platelet agents (excluding aspirin), cholinesterase inhibitors for Alzheimer's disease, or insulin. All genotyped individuals were of European descent. Cache-County study. The Cache-County Study was initiated in 1994 to investigate the association of APOE genotype and environmental exposures on cognitive function and dementia. A cohort comprised of 5,092 Cache County, Utah, residents (representing 90% of all individuals in the county who were aged 65 or older) has been followed continually for over 15 years, completing four triennial waves of data collection including clinical assessments 13 . Genotypes were obtained for 255 demented individuals and 2,471 elderly cognitively normal individuals 13 . All individuals genotyped were of European descent. UK-NIA data set. A description of the UK-NIA data set can be found in another paper 7 . In brief, this data set includes WES from 143 Alzheimer's disease cases and 183 elderly control individuals without dementia. All subjects were of European descent. University of Pittsburgh data set. The PLD3(V232M) variant was genotyped in 2,211 subjects including 1,253 Alzheimer's disease cases (62.6% females) and 958 elderly control individuals without dementia(64.3% females). A complete description of the data set can be found in another paper 14 . All individuals were of European descent. Toronto data set. The Toronto data set was composed of 269 unrelated Alzheimer's disease cases (53% females) and 250 unrelated controls without dementia (56% females) of European descent. The mean (s.d.) age at onset of Alzheimer's disease was 73 (68) years, and the mean age (s.d.) at last examination of the controls was 73 (610) years. The study was approved by the IRBs of the University of Toronto. Exome sequencing. Enrichment of coding exons and flanking intronic regions was performed using a solution hybrid selection method with the SureSelect human all exon 50Mb kit (Agilent Technologies) following the manufacturer's standard protocol. This step was performed by the Genome Technology Access Center at Washington University. The captured DNA was sequenced by paired-end reads on the HiSeq 2000 sequencer (Illumina). Raw sequence reads were aligned to the reference genome hg19 using Novoalign (Novocraft Technologies). Base and SNP calling was performed by SNP Samtools. SNP annotation was carried out using version 5.07 of SeattleSeq Annotation server (see URL) 20 . On average, 95% of the exome had greater than eightfold coverage. SNP calls were made using SAM tools 30 . SNPs identified with a quality score lower than 20 and a depth of coverage lower than 5 were removed. More than 2,500 novel variants in the coding region were found per individual. We identified all variants shared by the affected individuals in a family. Variants not present in 1,000 genome project or the Exome Variant Server (EVS: http://evs.gs.washington.edu/EVS/) or with a frequency lower than 0.5% in the EVS were selected. On average, 80 coding variants were selected for each family. The selected variants were then genotyped in the remaining sampled family members. We validated more than 98% of the selected variants, confirming the high specificity of our exome-sequencing method and analysis. On average, we genotyped a total of 13 family members (7 cases and 6 controls) per family. SNP genotyping. SNPs were genotyped using the Illumina Golden Gate, Sequenom, Kaspar and/or Taqman genotyping technologies. Only SNPs with a genotyping call rate higher than 98% and in Hardy-Weinberg equilibrium were used in the analyses. The principle of the MassARRAY system is PCR-based, with different size products analysed by SEQUENOM MALDI-TOF mass spectrometry 21, 31 . The KBioscience Competitive Allele-Specific PCR (KASP) system is FRET-based endpoint-genotyping technology, v4.0 SNP (KBioscience) 21, 31 . Genotype call rates were greater than 98%. PLD3 sequencing. PLD3 was sequenced in 2,363 cases and 2,027 controls of European origin, and 130 cases and 172 controls of African American descent using a pooled-DNA sequencing design as described previously 9, 23, 32 . In brief, equimolar amounts of individual DNA samples were pooled together following quantification using the Quant-iT PicoGreen reagent. Pools contained 100 ng of DNA per individual, from 94 individuals. The coding exons and flanking regions (a minimum of 50 bp each side) were individually PCR amplified using specific primers and Pfu Ultra high-fidelity polymerase (Stratagene). An average of 20 diploid genomes (approximately 0.14 ng DNA) per individual were used as input. PCR products were cleaned using QIAquick PCR purification kits, quantified using Quant-iT PicoGreen reagent and ligated in equimolar amounts using T4 Ligase and T4 Polynucleotide Kinase. After ligation, concatenated PCR products were randomly sheared by sonication and prepared for sequencing on an Illumina HighSeq2000 according to the manufacturer's specifications. pCMV6-XL5 amplicon (1,908 base pairs) was included in the reaction as a negative control. As positive controls, ten different constructs (p53 gene) with synthetically engineered mutations at a relative frequency of one mutated copy per 188 normal copies was amplified and pooled with the PCR products.
Paired-end reads (101 bp) were aligned to the human genome reference assembly build 36.1 (hg19) using SPLINTER 32 . SPLINTER uses the positive control to estimate sensitivity and specificity for variant calling. The wild type: mutant ratio in the positive control is similar to the relative frequency expected for a single mutation in one pool (1 chromosome mutated in 94 samples 5 1 in 188 chromosomes). SPLINTER uses the negative control (first 900 bp) to model the errors across the 101-bp Illumina reads and to create an error model from each sequencing run. Based on the error model SPLINTER calculates a P value for the probability that a predicted variant is a true positive. A P value at which all mutants in the positive controls were identified was defined as the cut-off value for the best sensitivity and specificity. All mutants included as part of the amplified positive control vector were found upon achieving .30-fold coverage at mutated sites (sensitivity 5 100%) and only ,80 sites in the 1,908-bp negative control vector were predicted to be polymorphic (specificity 5 95%). The variants with a P value below this cut-off value were considered for follow-up genotyping confirmation. All rare missense or splice-site variants were then validated by Sequenom and KASPar genotyping in each individual included in the pools. To avoid any batch or plate effects, cases and controls were included in each genotyping plate and all genotyping was performed in a single experiment. Finally, to confirm all of the LETTER RESEARCH heterozygous calls, we created a custom DNA plate including all of the heterozygotes (cases and controls) for all of the variants, and then genotyped them again by Sequenom, creating a new Sequenom set. Gene-expression and alternative splicing analyses. Total RNA was extracted using the RNeasy mini kit (Qiagen) following the manufacturer's protocol from 82 Alzheimer's disease cases and 39 individuals without dementia. Extracted RNA was treated with DNase1 to remove any potential DNA contamination. cDNAs were prepared from the total RNA, using the High-Capacity cDNA Archive kit (ABI). Gene-expression levels were analysed by real-time PCR, using an ABI-7900 real-time PCR system. The PLD3(A442A) variant was genotyped in DNA extracted from parietal lobe of 82 Alzheimer's disease cases and 39 individuals without dementia by KASPar as explained below. A total of eight carriers for the Ala442Ala variant were identified.
Total PLD3 expression: gene expression was analysed by real-time PCR, using an ABI-7500 real-time PCR system. TaqMan assays were used to quantify PLD3 mRNA levels. Primers and TaqMan probe for the reference gene, GAPDH, were designed over exon-exon boundaries, using Primer Express software, v3 (ABI) (sequences available on request). Cyclophilin A (ABI: 4326316E) was also used as a reference gene. Each real-time PCR run included within-plate triplicates and each experiment was performed at least twice for each sample.
Alternative splicing: we selected eight Ala442Ala carriers as well as eight CDR-, age-, APOE-and PMI-matched individuals to analyse the expression level of exon 11 containing transcripts, the exon in which the Ala442Ala variant is located. Realtime PCR assays were used to quantify PLD3 exon 7 (forward primer, 59-GCAGC TCCATCCCATCAACT-39; reverse, 59-CTTGGTTGTAGCGGGTGTCA-39), exon 8 (forward primer, 59-CTCAACGTGGTGGACAATGC-39; reverse, 59-AGTGG GCAGGTAGTTCATGACA-39), 9 (forward primer, 59-ACGAGCGTGGCGTCA AG-39; reverse, 59-CATGGATGGCTCCGAGTGT-39), 10 (forward primer, 59-G GTCCCCGCGGATGA-39; reverse, 59-GGTTGACACGGGCATATGG-39) and 11 (first pair of primers: forward primer, 59-CCAGCTGGAGGCCATTTTC-39; reverse, 59-TGTCAAGGTCATGGCTGTAAGG-39; second pair forward primer, 59-GCTGCTGGTGACGCAGAAT-39; reverse, 59-AGTCCCAGTCCCTCAGGA AAA-39). Two pairs of primers were designed for exon 11 as an internal control. SYBR-green primers were designed using Primer Express software, v3 (ABI). Each real-time PCR run included within-plate duplicates and each experiment was performed at least twice for each sample. Real-time data were analysed using the comparative Ct method. Only samples with a standard error of ,0.15% were analysed. The Ct values for exon 11 were normalized with the Ct value for the exons 7-10. The relative exon 11 levels for the Ala442Ala carriers versus the non-carriers were compared using a t-test. PLD3 gene expression in public databases. We also used the GEO data sets GSE15222 (ref. 33 ) and GSE5281 (ref. 26) to analyse the association of PLD3 gene expression and case-control status. In the GSE15222 data set, there are genotype and expression data from 486 late onset Alzheimer's Disease cases and 279 neuropathologically normal individuals without dementia. In the GSE5281 data set, samples were laser-captured from cortical regions of 16 normal elderly humans (10 males and 4 females) and from 33 Alzheimer's disease cases (15 males and 18 females). Mean age of cases and controls was 80 years. All samples were run on the Affymetrix U133 Plus 2.0 array. RNA data were re-normalized to an average expression of 8 units on a log 2 scale. As potential covariates we analysed the brain region, gender and age for each sample. Stepwise discriminant analysis was used to identify the potential covariates to be included in the analysis of covariance (ANCOVA). For this data set we also extracted the gene-expression levels for APP (probe 211277_x_at), PSEN1 (1559206_at) and PSEN2 (203460_s_at) to examine the correlation between PLD3 and APP, PSEN1 and PSEN2 using the Pearson correlation method. Human brain samples and analysis of the Affymetrix Human Exon 1.0 ST array. Quantification and analysis of PLD3 gene expression in brains was performed as previously described 34 . In brief, the human data used here were provided by the UK Human Brain Expression Consortium 34 and consisted of 101 control post-mortem brains. All samples originated from individuals with no significant neurological history or neuropathological abnormality and were collected by the MRC Edinburgh Brain Bank 35 , ensuring a consistent dissection protocol and sample handling procedure. A summary of the available demographic details of these samples including a thorough analysis of their effects on array quality is provided in another paper 36 . All samples were accompanied by fully informed consent for retrieval and were authorized for ethically approved scientific investigation (Research Ethics Committee number 10/H0716/3). Total RNA was isolated from human post-mortem brain tissues using the miRNeasy 96-well kit (Qiagen). The quality of total RNA was evaluated by the 2100 Bioanalyzer (Agilent) and RNA 6000 Nano Kit (Agilent) before processing with the Ambion WT Expression Kit and Affymetrix GeneChip Whole Transcript Sense Target Labelling Assay and hybridization to the Affymetrix Exon 1.0 ST. All arrays were pre-processed using Robust Multi-array Average using Partek Genomics Suite v6.6 (Partek). The resulting expression data were corrected for individual effects (within which are nested post-mortem interval, brain pH, sex, age at death and cause of death) and experimental batch effects (date of hybridization). Transcript-level expression was calculated for 26,993 genes using Winsorized means (Winsorizing the data below 10% and above 90%). RNA-pathway analysis. To evaluate the biological and functional relevance of coexpressed genes within the PLD3-containing modules, we used Weighted Gene Co-expression Network Analysis (WGCNA) and DAVID v6.7 (http://david.abcc. ncifcrf.gov/), the database for annotation, visualization and integrated discovery 37 . We restricted WGCNA to 15,409 transcripts that passed the Detection Above Background (DABG) criteria (P , 0.001 in at least 50% of samples in at least one brain region), had a coefficient of variation .5% and expression values exceeding 5 in all samples in at least one brain region. We followed a step-by-step network construction and module detection. In short, for each brain region, the Pearson correlations between all genes across all relevant samples were derived. We then calculated a signed-weighted co-expression adjacency matrix, allowing us to consider only positive correlations. A power 12, the default soft-threshold parameter for constructing a signed weighted network 38 , was used in all brain regions, after checking that this threshold recapitulated scale-free topology 39 . Topological overlap, a more biologically meaningful measure of node interconnectedness (similarity) 9, 23 than correlation, was subsequently calculated and genes were hierarchically clustered using 1 2 topological overlap as the distance measure. Finally, modules were determined by using a dynamic tree-cutting algorithm. WGCNA led to the identification of several co-expression modules, ranging in number and size between the ten brain regions. We examined the overrepresentation (that is, enrichment) of the three Gene Ontology (GO) categories (biological processes, cellular components and molecular function) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways for each list of co-expressed genes with PLD3 for each tissue by comparing numbers of significant genes annotated with this biological category with chance. Statistical analyses. All of the single SNP analyses were performed using a Fisher's exact test, with no covariates included. Allelic association with risk for Alzheimer's disease was tested using 'proc logistic' in SAS including APOE genotype, age, PCs and study as covariates when available. Odds ratios with 95% confidence intervals and relative risks were calculated for the alternative allele compared to the most common allele using SAS. Association with age at onset (AAO) was carried out using the Kaplan-Meier method and tested for significant differences, using a proportional hazards model (proc PHREG, SAS) including gender and study as covariates. Controls without dementia were included in the analyses as censored data. The inclusion of these samples did not change the association. Gene-based analyses were performed using the optimal SNP-set (Sequence) Kernel Association Test (SKAT-O) 25 . Population attributable risk. We calculated the Population attributable risk (PAR) using the relative risk obtained in the study and the MAF from the EVS database (http://evs.gs.washington.edu/EVS/) and in the Cache-County data set, which is a population-based data set, using the equation: PAR~P e (RR e {1) 1zP e RR e {1 ð Þ ð Þ
where P e is the carrier frequency in the population and RR e is the relative risk for the different variants. Neuropathology studies. All study procedures were approved by Washington University's Human Research Protection Office. At autopsy, brain tissue was obtained from participants according to the protocol of the Knight-ADRC. Alzheimer's disease neuropathologic change was assessed according to the criteria of the National Institute on Ageing-Alzheimer's Association (NIA-AA) 40 . Dementia with Lewy bodies was assessed using the criteria given in another paper 41 . Cell-based studies. The following plasmids were used in this study: pCMV6-XL5 human PLD3-WT (Origene), pCS2-Myc human APP695-WT
42
, pCGN-PLD-WT 43 and Lys758Arg 44 , pCGN-PLD2-WT 45 and Lys898Arg 44 , pGFL-GFP 46 , pGFP-V-RS-PLD3-shRNA-GI548821 (Origene) and pGFP-V-RS-Scr-shRNA-TR30013 (Origene). A dominant-negative mutation (Lys418Arg) 18 was introduced into the pCMV6-XL5 human PLD3-WT vector by site-directed mutagenesis using the QuikChangeII Site-Directed Mutagenesis kit (Agilent). All constructs were verified by Sanger sequencing. Cell-culture assays. Human embryonic kidney (HEK293T) cells were cultured in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1% L-glutamine and penicillin/streptomycin (solution containing penicillin and streptomycin). HEK293T cells were grown in 6-well lysine-coated plates. Mouse neuroblastoma (N2A) cells stably expressing human APP695 wild type were cultured in DMEM and Opti-MEM (50:50) supplemented with 5% FBS, 1% L -glutamine, penicillin/streptomycin and 500 mg ml 21 G418. After reaching RESEARCH LETTER
